Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FDHT-PET assessment of androgen receptor blockade with bicalutamide in metastatic breast cancer
NL-OMON47891Phase 2Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bicalutamide in breast cancer, sponsored by University Medical Center Groningen. Primary endpoint: Primary statistical target. Started Feb 2016; status: active, not recruiting.
02
Drugs
bicalutamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON47891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47891.